Literature DB >> 2846074

Purification and partial characterization of membrane-associated type II (cGMP-activatable) cyclic nucleotide phosphodiesterase from rabbit brain.

M E Whalin1, S J Strada, W J Thompson.   

Abstract

Membrane-associated, Type II (cGMP-activatable) cyclic nucleotide phosphodiesterase (PDE) from rabbit brain, representing 75% of the total homogenate Type II PDE activity, was purified to apparent homogeneity. The enzyme was released from 13,000 x g particulate fractions by limited proteolysis with trypsin and fractionated using DE-52 anion-exchange, cGMP-Sepharose affinity and hydroxylapatite chromatographies. The enzyme showed 105 kDa subunits by SDS-PAGE and had a Stokes radius of 62.70 A as determined by gel filtration chromatography. Hydrolysis of cAMP or cGMP showed positive cooperativity, with cAMP kinetic behavior linearized in the presence of 2 microM cGMP. Substrate concentrations required for half maximum velocity were 28 microM for cAMP and 16 microM for cGMP. Maximum velocities were approx. 160 mumol/min per mg for both nucleotides. The apparent Kact for cGMP stimulation of cAMP hydrolysis at 5 microM substrate was 0.35 microM and maximal stimulation (3-5-fold) was achieved with 2 microM cGMP. Cyclic nucleotide hydrolysis was not enhanced by calcium/calmodulin. The purified enzyme can be labeled by cAMP-dependent protein kinase as demonstrated by the incorporation of 32P from [gamma-32P]ATP into the 105 kDa enzyme subunit. Initial experiments showed that phosphorylation of the enzyme did not significantly alter enzyme activity measured at 5 microM [3H]cAMP in the absence or presence of 2 microM cGMP or at 40 microM [3H]cGMP. Monoclonal antibodies produced against Type II PDE immunoprecipitate enzyme activity, 105 kDa protein and 32P-labeled enzyme. The 105 kDa protein was also photoaffinity labeled with [32P]cGMP. The purified Type II PDE described here is physicochemically very similar to the isozyme purified from the cytosolic fraction of several bovine tissues with the exception that it is predominantly a particulate enzyme. This difference may reflect an important regulatory mechanism governing the metabolism of cyclic nucleotides in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846074     DOI: 10.1016/0167-4889(88)90105-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation.

Authors:  I V Turko; S H Francis; J D Corbin
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

2.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

3.  Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes.

Authors:  Corina Russwurm; Georg Zoidl; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

4.  The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding.

Authors:  Sergio E Martinez; Albert Y Wu; Natalie A Glavas; Xiao-Bo Tang; Stewart Turley; Wim G J Hol; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

5.  Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.

Authors:  Kenichi Hiramoto; Taku Murata; Kasumi Shimizu; Hiroshi Morita; Madoka Inui; Vincent C Manganiello; Toshiro Tagawa; Naoya Arai
Journal:  Cell Signal       Date:  2014-04-03       Impact factor: 4.315

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.